Industry News (Joint Venture)

Agreement Signed To Develop Anti-Cancer Therapeutics

Published in Gene Therapy Weekly, December 25th, 1995

Mitotix Incorporated, Cambridge, Massachusetts, and DuPont Merck, Wilmington, Delaware, announced a collaborative agreement to develop and commercialize novel anti-cancer therapeutics that act on a group of enzymes called cyclin-dependent kinases (Cdks), that are essential for regulating the cell division cycle.

Through the agreement, DuPont Merck could invest up to $55 million in Mitotix in the form of equity, research, development and clinical milestone payments.

The collaboration is initially focusing on three of Mitotix's proprietary molecular targets. Under the terms of the agreement, DuPont Merck receives exclusive worldwide rights to develop...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-12-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry